Home › Open-Angle Glaucoma › NCT07228221

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

iStent Infinite and iDose TR for Management of Moderate to Severe Primary Open Angle Glaucoma Are a Safe and Effective Alternative to Filtering Surgery for IOP Reduction in Patients With Medically Uncontrolled Glaucoma. (POAG)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Moderate to severe open angle glaucoma (including POAG, PG, and PXG)
* Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9
* Visual acuity HM or better
* VF MD -6dB or worse
* Failed medical therapy and/or laser treatment
* Incisional glaucoma surgery contemplated as next intervention
* Phakic or pseudophakic

Exclusion Criteria:

* Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma
* Previous incisional glaucoma surgery
* ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days
* Active ocular inflammation or edema, clinically significant corneal dystrophy
* Corneal or other pathology preventing accurate Goldmann applanation tonometry

About the study

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

What is being tested

• iStent infinite trabecular micro-bypass system model iS3 (device)
• iDose TR (Travoprost intracameral Implant) 75mcg (drug)

Sponsor: Jonathon Myers · Participants: 20 · Started: Jan 5, 2026

Contact the study team

• Meskerem Divers · Phone: 215-825-4712
• Jeanne L Molineaux, COA · Phone: 215-825-4713

Official record on ClinicalTrials.gov — NCT07228221

Locations in the U.S.

Conditions

• Open-Angle Glaucoma

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.